FGFR2 amplification in colorectal adenocarcinoma.
Cold Spring Harb Mol Case Stud
; 3(6)2017 Nov.
Article
in En
| MEDLINE
| ID: mdl-28835367
ABSTRACT
FGFR2 is recurrently amplified in 5% of gastric cancers and 1%-4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not limited to only single-nucleotide polymorphisms and insertions/deletions but also to copy-number alterations.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Adenomatous Polyposis Coli
/
Receptor, Fibroblast Growth Factor, Type 2
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Cold Spring Harb Mol Case Stud
Year:
2017
Type:
Article
Affiliation country:
United States